Cargando…

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models

Specific targeting of the tumoral vasculature by vascular-disrupting agents (VDA), of which combretastatin A-4 (CA-4) is a main representative, has been considered a new therapeutic strategy against multidrug-resistant tumors. In addition, CA-4 and analogs are tubulin-targeting agents and can exert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reipsch, Franziska, Biersack, Bernhard, Lucas, Henrike, Schobert, Rainer, Mueller, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658273/ https://www.ncbi.nlm.nih.gov/pubmed/34884888 http://dx.doi.org/10.3390/ijms222313082

Ejemplares similares

Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
por: Schmitt, Florian, et al.
Publicado: (2019)

Guided Antitumoural Drugs: (Imidazol‐2‐ylidene)(L)gold(I) Complexes Seeking Cellular Targets Controlled by the Nature of Ligand L
por: Bär, Sofia I., et al.
Publicado: (2021)

2‐Amino‐4‐aryl‐5‐oxo‐4,5‐dihydropyrano[3,2‐c]chromene‐3‐carbonitriles with Microtubule‐Disruptive, Centrosome‐Declustering, and Antiangiogenic Effects in vitro and in vivo
por: Köhler, Leonhard H. F., et al.
Publicado: (2022)

3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors
por: Bär, Sofia I., et al.
Publicado: (2022)

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate
por: Holmes, Toby, et al.
Publicado: (2020)

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001)

3D-QSAR Study of Combretastatin A-4 Analogs Based on Molecular Docking
por: Jin, Yinghua, et al.
Publicado: (2011)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
por: Ibrahim, Mohamed A, et al.
Publicado: (2013)

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate
por: Williams, L J, et al.
Publicado: (2014)

Fluorinated and N-Acryloyl-Modified 3,5-Di[(E)-benzylidene]piperidin-4-one Curcuminoids for the Treatment of Pancreatic Carcinoma
por: Ghosh, Hindole, et al.
Publicado: (2023)

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate
por: Shepherd, Joanna, et al.
Publicado: (2017)

Antiparasitic Activity of Fluorophenyl-Substituted Pyrimido[1,2-a]benzimidazoles
por: Nasr, Ibrahim S. Al, et al.
Publicado: (2023)

New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3H)-benzothiazolones
por: Atanasov, Gjorgji, et al.
Publicado: (2021)

Analogs of the Catechol Derivative Dynasore Inhibit HIV-1 Ribonuclease H, SARS-CoV-2 nsp14 Exoribonuclease, and Virus Replication
por: Asthana, Abhishek, et al.
Publicado: (2023)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101
por: Bao, Xin, et al.
Publicado: (2021)

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
por: Parkins, C S, et al.
Publicado: (2000)

Synthesis and Anticancer Evaluation of New Indole-Based Tyrphostin Derivatives and Their (p-Cymene)dichloridoruthenium(II) Complexes
por: Oberhuber, Natalie, et al.
Publicado: (2023)

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study
por: Gaya, A, et al.
Publicado: (2008)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status
Publicado: (1998)

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
por: Beauregard, D. A., et al.
Publicado: (1998)

Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors
por: Goehringer, Nils, et al.
Publicado: (2021)

A New Synthetic Curcuminoid Displays Antitumor Activities in Metastasized Melanoma
por: Kaps, Leonard, et al.
Publicado: (2023)

Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities
por: Köhler, Leonhard H. F., et al.
Publicado: (2023)

Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent
por: Guimarães, Celina de Jesus, et al.
Publicado: (2023)

Disruption of insect immunity using analogs of the pleiotropic insect peptide hormone Neb-colloostatin: a nanotech approach for pest control II
por: Nowicki, Patryk, et al.
Publicado: (2021)

Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression
por: Dachs, Gabi U, et al.
Publicado: (2006)

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
por: Rowlands, Jordan, et al.
Publicado: (2018)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors
por: Kumar, Sunil, et al.
Publicado: (2013)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications
por: Karatoprak, Gökçe Şeker, et al.
Publicado: (2020)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

New 4,5-Diarylimidazol-2-ylidene–iodidogold(I) Complexes with High Activity against Esophageal Adenocarcinoma Cells
por: Schleser, Sebastian W., et al.
Publicado: (2023)

Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs
por: Farhan, Mohd, et al.
Publicado: (2019)

Publisher Correction: Disruption of insect immunity using analogs of the pleiotropic insect peptide hormone Neb-colloostatin: a nanotech approach for pest control II
por: Nowicki, Patryk, et al.
Publicado: (2021)

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_lihf1o6jc41hgued0clul1mlm8